Morgan Stanley’s Zenas BioPharma ZBIO Stock Holding History

Morgan Stanley’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.83M	Sell	93,396 -34,939	-27%	-$784K	﹤0.01%	4823
2025 Q4	$4.66M	Buy	128,335 +39,602	+45%	+$1.3M	﹤0.01%	4233
2025 Q3	$1.97M	Sell	88,733 -35,568	-29%	-$579K	﹤0.01%	4800
2025 Q2	$1.2M	Buy	124,301 +46,391	+60%	+$452K	﹤0.01%	5004
2025 Q1	$615K	Sell	77,910 -280,302	-78%	-$2.19M	﹤0.01%	5241
2024 Q4	$2.93M	Buy	358,212 +307,162	+602%	+$4.79M	﹤0.01%	4420
2024 Q3	$864K	Buy	+51,050	New	+$918K	﹤0.01%	5124

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Morgan Stanley's ZBIO Position: Q1 2026 in Review

Morgan Stanley reduced its Zenas BioPharma (ZBIO) stake by 27% in Q1 2026, selling an estimated $784K and leaving 93,396 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #4823.

Morgan Stanley first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.66M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Morgan Stanley held 93,396 shares of Zenas BioPharma worth $1.83M as of Q1 2026.
Morgan Stanley sold 34,939 Zenas BioPharma shares in Q1 2026, an estimated $784K.
Zenas BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4823 holding.
Morgan Stanley first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
Morgan Stanley's Zenas BioPharma position peaked at $4.66M in Q4 2025.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.